Open Clinical Trials

Breast

  • An Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-negative, PR-negative and HER2-negative Metastatic Breast Cancer
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • A Randomized, Open Label Study of Lapatinib plus Trastuzumab vs. Trastuzumab as Continued HER2 Supression Therapy After Completion of 1st or 2nd Line Trastuzumab Plus Chemo in Subjects with HER2 Positive Metastatic Breast Cancer
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • Phase II Open Label Stuey of Trabectedin (Yondelis) in Metastatic Known BRCA1 or BRCA2 Mutation Carriers
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • Phase II Trial of Ixabenpilone plus Carboplatin in Patients with Metastatic Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Comibnation in Patients with HER/2/ErbB2 Positive Primary Breast Cancer
    Available at: Medical Center,  New Braunfels, 
  • A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • Randomized Phase II Trial of Letrozole with or without Dasatinib as First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) Following Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Stone Oak, 
  • Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • Phase II Randomized Trial of Fulvestrant with or without Dasatinib in Men and Postmenopausal Women who have Hormone Receptor-positive Advanced Breast Cancer Previously Treated with an Aromatase Inhibitor
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 

Breast Cancer and Bone Metastases

  • A Prospective, Randomized Double-Blind, Stratified, Placebo-Controlled, Multi-Center, Three-Arm Trial of the Continued Efficacy and Safety of Zometa (every 4 weeks vs. every 12 weeks vs. placebo) in Patients with Documented Bone Metastases from Breast Cancer
    Available at: Medical Center,  New Braunfels, 

DVT

  • A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study for the Evaluation of Efficacy and Safey of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism
    Available at: Medical Center,  New Braunfels, 
  • A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
    Available at: Medical Center,  New Braunfels, 

Gastrointestinal

  • A Randomized, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib versus Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
    Available at: Kerrville,  Northeast,  Stone Oak, 

Genitourinary

ITP (Idiopathic Thrombocytopenic Purpura)

  • An Open Label Safety Study of S-88871 in Adult Subjects with Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without a Prior Splenectomy
    Available at: Medical Center,  New Braunfels, 
  • Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once Daily for 42 Days to Adult Subjects with Relapsed Persistent or Chronic ITP With or Without Prior Splenectomy
    Available at: Medical Center,  New Braunfels, 

Leukemia (CLL, CML)

Liver

  • A Randomized, Phase III, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Everolimus in Adult Patients with Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment (The EVOLVE-1 Study)
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of it's Treatment with SorafeNib
    Available at: Kerrville,  Metropolitan,  Stone Oak, 

Lung

  • Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer
    Available at: Medical Center,  New Braunfels, 
  • Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ig Once-Every-3-Weeks to a Hemoglobiin Ceiling of 12.0 g/dl in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Stone Oak, 
  • Randomized Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Stone Oak, 

Lymphoma

  • An Open-Label Study to Evaluate the Efficacy and Safety of Treatment with Bendamustine in Combination with Ofatumumab in Previously Untreated Patients with Indolent B-Cell Non-Hodkin's Lymphoma
    Available at: Medical Center,  New Braunfels, 
  • Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma
    Available at: Medical Center,  New Braunfels, 
  • An Open-Label , Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma
    Available at: Kerrville,  Metropolitan,  Stone Oak, 
  • An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
    Available at: Kerrville,  Medical Center,  Metropolitan,  New Braunfels,  Stone Oak, 
  • A Phase III Multicenter, Open Label Study of Rituximab Faster Infusion Time In Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkins Lymphoma
    Available at: Medical Center,  New Braunfels, 

Malignant Melanoma

  • Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Patients With Unresectable Stage III or IV Melanoma
    Available at: Kerrville, 

Multiple Myeloma

Myelodysplasia

  • Phase I Dose-Ranging Study of Ezatiostat Hydrochloride (tablets) in Combination with Revlimid in patients with Non-Deletion (5q) Low to Intermediate-1 Risk MDS
    Available at: Medical Center,  New Braunfels, 
  • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Deferasirox in Patients with Myelodysplastic Syyndromes (low/int-1 Risk) and Transfusional Iron Overload
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • A Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced MDS or Secondary AML after MDS
    Available at: Medical Center,  New Braunfels, 

Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia

  • A Phase I, Open-Label, Dose Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously and as Different Oral Formulations in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma
    Available at: Medical Center,  New Braunfels, 

Severe Chronic Neutropenia

  • Phase 2, Randomized Study of Ezatiostat Hydrochloride (Telindra, TLK199 Tablets) for Treatment of SCN
    Available at: Medical Center,  New Braunfels, 

Thymic

  • Phase II Study of Oral PHA-848125AC in Patients with Thymic Carcinoma Previously Treated with Chemotherapy (CDKO-125a-006)
    Available at: Kerrville,  Metropolitan,  Stone Oak,